Clinical trials: Bladder, Overactive
Overactive Bladder, Urgency-Frequency
Comparison of Motor and Sensory Response With Interstim Stimulation
Sacral nerve stimulation (SNS) implantation is a minimally invasive procedure which has current FDA approval for urinary urge incontinence, urgency-frequency syndrome and non-obstructive urinary retention, and has been available…
- Trial name
- NCT00943904
- Testing
- Interstim implant for SNS
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of California, Irvine
Overactive Bladder, Urinary Incontinence
Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence
The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.
- Conditions
- Overactive Bladder, Urinary Incontinence, Children
- Trial name
- NCT00603343
- Testing
- Mictonetten 5 mg, coated tablet
- Volunteers
- 303 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
Overactive Bladder
Overactive Bladder Telemedicine Non-inferiority Trial
In this study, the investigators aim to validate the telemedicine paradigm as a feasible alternative to traditional in-person clinic visits for the management of overactive bladder (OAB).
- Trial name
- OAB Telemed (NCT05117918)
- Testing
- SUFU Clinical Care Pathway for Overactive Bladder, Telemedicine
- Where
- United States
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Bladder Hyperactivity
Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder Patients
Unilateral sacral neuromodulation (SNM) has emerged as a valuable treatment for patient with low urinary tract dysfunction when failure or bad tolerance to anticholinergic treatment for overactive bladder.
- Trial name
- NEUROBIL (NCT01960270)
- Testing
- Device: INTERSTIM II
- Where
- 12 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Rouen
Neurogenic Detrusor Overactivity
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity
This is a prospective, multicentre (7 sites), randomized, double-blind, study comparing intravesical injection of BOTOX to placebo in 56 subjects with NDO secondary to spinal cord injury or multiple sclerosis.
- Trial name
- NCT01091727
- Testing
- Botulinum toxin A
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- Sunnybrook Health Sciences Centre
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
The goal of this clinical trial is to test the effect of a supplement called MitoQ (mitoquinol mesylate) on bladder symptoms such as urgency and frequency in women 50 years and older who have the metabolic syndrome.
- Trial name
- Mito-LUTS (NCT06351683)
- Testing
- MitoQ (mitoquinol mesylate)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Iman Al-Naggar, PhD
Overactive Bladder Syndrome
Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract Symptoms
The purpose of this study is to assess the prevalence of mycoplasma hominis, ureaplasma urealyticum, neisseria gonorrhea, and chlamydia trachomatis in women with overactive bladder symptoms, and to correlate these findings with…
- Trial name
- NCT01559623
- Testing
- retrospective data analysis
- Where
- Switzerland
- Volunteers
- 766 people
- Sponsor
- University of Zurich
Urinary Bladder, Overactive
Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine…
- Trial name
- VERSUS (NCT00454740)
- Testing
- solifenacin succinate
- Where
- 104 sites in United States
- Volunteers
- 441 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder, Urinary Incontinence
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00915525
- Testing
- botulinum toxin Type A
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 829 people
- Sponsor
- Allergan
Overactive Detrusor, Neurogenic Bladder
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition.
- Trial name
- NCT01192568
- Testing
- Oxybutynin
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Urinary Incontinence
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound.
- Trial name
- NCT00137397
- Testing
- Tolterodine ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Multiple Sclerosis, Overactive Bladder
PTNS for Female Patients Suffering From Multiple Sclerosis
This is a pilot, single blind, randomized, sham-controlled trial to assess the benefit of Percutaneous Tibial Nerve Stimulation (PTNS) in treating bladder overactivity (OAB) symptoms in multiple sclerosis (MS) patients.
- Trial name
- PTNS-MS (NCT05422625)
- Testing
- PTNS Treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Corewell Health East
Overactive Bladder Syndrome, Urinary Incontinence
Improving Overactive Bladder Treatment Access and Adherence
Overactive bladder (OAB) and urinary incontinence (UI) are chronic debilitating and embarrassing conditions that affect 33 million Americans.
- Trial name
- NCT06094543
- Testing
- Patient Engagement Tool
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Stanford University
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase
Rationale: The sensation of the need for urination (urge) is a complex and only partially understood mechanism. It is our hypothesis that this mechanism is disrupted in patients suffering from overactive bladder syndrome.
- Trial name
- NCT00628615
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Overactive Bladder
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
- Trial name
- NCT01220726
- Testing
- Botox
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Overactive Bladder
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
This extension trial of SP668 consists of two phases: double-blind treatment and open-label extension. The trial provides subjects the option of long-term treatment with sustained release (SR) fesoterodine (SPM 907) and to assess…
- Trial name
- NCT00220389
- Testing
- SPM 907
- Where
- United States
- Sponsor
- Pfizer
Quality of Life
Health-related QoF Between OAB-wet and OAB-dry Women
Overactive bladder syndrome (OAB) has a great negative impact on health-related quality of life. In literatures, few studies reported the comparisons of health related quality of life between OAB-wet and OAB-dry female patients.
- Trial name
- NCT03806855
- Testing
- Bladder diary
- Volunteers
- 1,071 people
- Sponsor
- National Taiwan University Hospital
Overactive Bladder
Cystoscopic Ablation Via RF Energy Clinical Trial
Phase I/II study to assess the safety and performance of the Amphora OAB system for treatment of urgency and frequency with or without urge incontinence caused by an overactive bladder.
- Trial name
- CARETI (NCT02398578)
- Testing
- Amphora OAB Device
- Where
- 4 sites in Belgium, Canada
- Volunteers
- 63 people
- Sponsor
- Amphora Medical, Inc.
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Overactive Bladder, Overactive Urinary Bladder
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
The study is designed to investigate the effects of the investigational drug vibegron (MK-4618) compared to placebo on maximum urinary bladder capacity in women with overactive bladder.
- Trial name
- NCT01500382
- Testing
- Vibegron, Tolterodine ER, Prophylactic Antibiotic
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC